ReviewCurrent rheumatology reports2006
Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology.
Review in Current rheumatology reports, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Treatment recommendations for psoriatic arthritis.Annals of the rheumatic diseases · 2009Guideline
- Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment.BMC dermatology · 2014Trial
- Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis.Frontiers in medicine · 2023Article
- [The skin and rheumatism].Der Orthopade · 2019Review
- Psoriatic arthritis.F1000Research · 2019Review
- Disease activity and biologic use in patients with psoriatic arthritis or rheumatoid arthritis.Clinical rheumatology · 2018Observational
- Diagnosis and management of psoriasis.Canadian family physician Medecin de famille canadien · 2017Review
- [Psoriatic arthritis : Overview of drug therapy options and administration characteristics].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2017Review
- [Psoriatic arthritis : Overview of drug therapy options and administration characteristics].Zeitschrift fur Rheumatologie · 2016Review
- Prevalence of acute and chronic viral seropositivity and characteristics of disease in patients with psoriatic arthritis treated with cyclosporine: a post hoc analysis from a sex point of view on the observational study of infectious events in psoriasis complicated by active psoriatic arthritis.Clinical, cosmetic and investigational dermatology · 2016Article
- Review
- Prevalence of past and reactivated viral infections and efficacy of cyclosporine A as monotherapy or in combination in patients with psoriatic arthritis--synergy study: a longitudinal observational study.BioMed research international · 2014Observational
- Psoriatic arthritis: pharmacotherapy update.Current rheumatology reports · 2010Review
- Can we identify psoriatic arthritis early?Current rheumatology reports · 2008Article
- Adalimumab in dermatology.British journal of clinical pharmacology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriatic arthritis is an inflammatory arthritis, which occurs in up to 30% of individuals with psoriasis. Dermatologists and other physicians treating psoriasis are in an ideal position to screen for the condition, and with rheumatologists, strategize optimal therapy. Mild skin and joint manifestations may be treated effectively with topical agents, ultraviolet light therapy, and nonsteroidal anti-inflammatory drugs. More severe manifestations of the disease, including progressive peripheral joint damage, spine disease, enthesitis, dactylitis, and severe skin changes, require systemic therapy. Traditional systemic agents include methotrexate, sulfasalazine, and cyclosporine. When these agents are not adequate or not tolerated, new biologic agents, particularly anti-tumor necrosis factor (TNF) compounds, have shown significant and enduring benefit in all disease domains, improvement in quality of life and function, and inhibition of progressive joint damage.
Indexed as
Identifiers
16973108What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.